<p fr-original-style="" style="margin-top: 0px; margin-bottom: 1em; box-sizing: border-box;">• <a fr-original-style="" href="https://www.bloomberg.com/news/articles/2023-01-24/eli-lilly-lly-plans-manufacturing-expansion-as-obesity-drug-demand-looms" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank"><strong fr-original-style="" style="font-weight: 700; box-sizing: border-box;">US pharmaceutical Eli Lilly</strong></a> is planning an expansion worth $450 million (€414mn) to its manufacturing site in North Carolina, which will double the production of its diabetes drug with the potential to treat obesity. Demand grows for Mounjaro, Lilly’s drug that mimics incretin, a hormone that gives the sensation of having eaten. The trend is a part of the soaring demand for drugs that can help with weight loss.&nbsp;</p>

weight loss ile ilgili hikayeler